News & Events
| Aug 15, 2011 | Dynamix featured as a leader in cancer metabolism in a Biocentury article read more |
| Aug 3, 2011 | Dynamix reports new Preclinical Data for DNX-04042 Supporting Development in Rheumatoid Arthritis read more |
| Jul 10, 2011 | Dynamix’s novel agent DNX-04042 significantly inhibits B cell lymphoma read more |
| Apr 12, 2011 | Dynamix to Present its PKM2 Cancer Metabolism Program at ASCO Annual Meeting 2011 read more |
| Jan 25, 2011 | Dynamix to Present its PKM2 Cancer Metabolism Program at AACR102 read more |
| Dec 5, 2010 | Prof. Philip Schein Joins Dynamix Pharmaceuticals Clinical Advisory Board read more |
| Nov 11, 2010 | Prof. Eyal Gottlieb, an Expert on Cancer Metabolism, Joins Dynamix Advisory Board read more |
| May 10, 2010 | Prof. Ofer Shpilberg Joins Dynamix Pharmaceuticals Clinical Advisory Board read more |
| May 28, 2009 | Dynamix Appoints Morris Laster, M.D., to Board of Directors read more |
| Feb 16, 2009 | Dynamix Pharmaceuticals Signs a Collaboration Deal with Teva Pharmaceutical Industries read more |
| Feb 16, 2009 | Dynamix Pharmaceuticals Completes a $10M Series A Financing read more |
News & Events